


Date: December 10, 2003

Page 1 of 2

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. S&H-010DX	APPLICATION NO. 10/664,678
 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT: Walter Schubert	
		FILING DATE 9/12/03	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
C.C.	DE 197 23 690 A**	3/26/98	Germany (English Abstract)			<input checked="" type="checkbox"/>

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

C.C.	"Fundamental Immunology", Paul W.E. ed. Lippincott-Raven Publishers, Philadelphia, 1999, pp. 66-67 of Chapter 3**
	Pullen et al., "Ultrastructural analysis of spinal motoneurons from mice treated with IgG from ALS patients, healthy individuals, or disease controls", J. Neurol. Sci. 20-00; 180:35-45**
	Obal et al., "Recruitment of activated microglia cells in the spinal cord of mice by ALS IgG", NeuroReport 2001; 12:2449-2452**
	Schubert, et al., "Detection by 4-parameter microscopic imaging and increase of rare mononuclear blood leukocyte types expressing..." Neuroscience Letters, vol. 198, no. 1, 9/22/95**
	Kahan, "immunosuppressive therapy" Cur. Opin. Immunol. 4:553-560 1992**
	Tan et al., "Immunosuppressive Treatment of Motor Neuron Syndromes", Arch Neurol. 51:194-200 1994**
	Dalakas et al., "Effect of High-Dose Intravenous Immunoglobulin on Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy", Arch Neurol. 51:861-864 1994**
	Ludolph J., "Treatment of amyotrophic lateral sclerosis - What is the next step?", Neurol. 247:13-18 2000**
	Serratrice et al., "Overview of the Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis", Adv. Neurol 68:1-5 1995**
	D.D.F. Ma et al., "Synthetic oligonucleotides as therapeutics" the coming of age", Biotechnology Annual Review, Vol. 5, pp. 155-196**
	C. Frank Bennett et al., "Pharmacology of Antisense Therapeutic Agents", Methods in Molecular Medicine: Antisense Therapeutics, pp. 13-46**
	Andrea D. Branch, "A good antisense molecule is hard to find", TIBS 23 - February 9198, pp. 45-50**
	W. Michael Flanagan et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide", Research, pp. 1-5**
C.C.	Hans Fritz et al., "Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides", Journal of Colloid and Interface Science, 195, pp. 272-288**


EXAMINER <i>ca</i> <i>ef</i>	DATE CONSIDERED 7/29/05
---------------------------------	----------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**THESE REFERENCES CAN BE FOUND IN RELATED PATENT NOS. 6,638,506, AND 6,638,515 AND APPLICATION NOS. 09/802,305 AND 09/803,614

Date: December 10, 2003

Page 2 of 2

Form PTO-1449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. S&H-010DX		APPLICATION NO. 10/664,678	
 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				APPLICANT: Walter Schubert			
				FILING DATE 9/12/03		GROUP 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
C. C.		Kuang-Yu Jen et al., Stem Cells, 2000; 18; pp. 307-319					
C. C.		Sudhir Agrawal, Antisense Oligonucleotides: towards clinical trials, TIBTECH, October 1996; Vol. 14, pp. 376-387					
C. C.		Douglas W. Green, et al., Antisense Oligonucleotides: An Evolving Technology for Modulation of Gene Expression in Human Disease, COLLECTIVE REVIEW, Journal AM. Coll. Surg.; pp. 93-105					
C. C.		Traian V. Chirila et al., "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides", Biomaterials 23 (2992) pp. 321-342					
C. C.		Sudhir Agrawal et al., "Antisense therapeutics: is it as simple as complementary base recognition?", Molecular Medicine Today; February 2000, Vol. 6, pp. 72-81					
EXAMINER				DATE CONSIDERED			
Chun Crowder				07-29-2005			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**THESE REFERENCES CAN BE FOUND IN RELATED PATENT NOS. 6,638,506 AND 6,638,515 AND APPLICATION NOS. 09/802,305 AND 09/803,614